OS Therapies eyes global osteosarcoma vaccine approvals after Phase IIb win
OS will now seek approval for OST-HER2’s in the indication throughout the UK, US and EU.
13 October 2025
13 October 2025
OS will now seek approval for OST-HER2’s in the indication throughout the UK, US and EU.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.